The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
FDA mandates clearer drug ads, Merck expands oncology portfolio, and political shifts raise questions about public health leadership.
Gilead’s twice-yearly injectable PrEP shows near-perfect efficacy, prompting global access initiatives and a rethinking of HIV prevention strategies.
A landmark Phase 3 clinical trial led by researchers at Mass General Brigham has demonstrated that inebilizumab, a …
AbbVie’s Emraclidine Misses Mark in Schizophrenia Trials—But Safety Signals Keep Hope Alive
Novo Nordisk’s oral obesity drug shows superior efficacy over Eli Lilly’s candidate, reshaping the competitive landscape in metabolic …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
Advanced manufacturing technologies are transforming biopharma production lines, driving efficiency, quality, and scalability to meet growing global demand.
Already a subscriber? Log in